Pulmonary/Respiratory Diseases | Preclinical Developments

Cynata Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Cymerus MSCs Demonstrate Efficacy in Preclinical Lung Disease Study

Lead Product(s): Cymerus mesenchymal stem cells

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 08, 2020

Details:

Treatment with Cynata’s Cymerus MSCs led to statistically significant improvements in multiple harmful effects of IPF, including interstitial fibrosis, dynamic lung compliance and airway resistance.

BioAegis Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

BioAegis Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia

Lead Product(s): Recombinant human plasma gelsolin

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 04, 2020

Details:

The compelling data from this NIH sponsored study show the potential of gelsolin to not only improve survival, but to diminish lung injury caused by virulent pneumonia.

ContraFect Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Contrafect Announces Funding Agreement with the Cystic Fibrosis Foundation

Lead Product(s): Exebacase

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: CF-370

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Cystic Fibrosis Foundation

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Funding August 25, 2020

Details:

First stage of the agreement will fund in vitro activity of ContraFect’s next product candidate, CF-370, an engineered lysin targeting Pseudomonas aeruginosa, and amurin peptides, against bacterial specimens obtained from CF patients at different stages of disease.

Morphic Therapeutic

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Morphic Announces that Abbvie Exercises License Option to Αvβ6 Integrin Inhibitor Program, Including Morf-720, for Fibrotic Diseases

Lead Product(s): MORF-720

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MORF-720

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: AbbVie Inc

Deal Size: $120.0 million Upfront Cash: $100.0 million

Deal Type: Licensing Agreement August 25, 2020

Details:

AbbVie has exercised a license option under the companies’ research and development collaboration agreement to develop Morphic’s αvβ6 integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.

Asalyxa Bio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Asalyxa Bio Launches with Novel Neutrophil-Targeting Drug Delivery Platform Technology and Lead Candidate, ASX-100

Lead Product(s): ASX-100

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ASX-100

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Orange Grove Bio

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Funding August 25, 2020

Details:

ASX-100 is a novel, spherical polymer particle that degrades into salicylic acid – an active metabolite of aspirin – and a food additive that is listed as GRAS (generally regards as safe) by the FDA. Seed funding will be used in first-in-human trials of the drug.

Nuformix

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Nuformix Reports Results from Pre-clinical Pilot Study in IPF for NXP004 Programme

Lead Product(s): NXP004

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NXP004

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 19, 2020

Details:

NXP004 showed a dose-dependent reduction in the secretion of several key ECM components.These data suggest NXP004 compares favourably to current standard of care with regard to anti-fibrotic activity in this model.

Redx Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Redx Signs Out Licensing Agreement With Astrazeneca

Lead Product(s): RXC006

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RXC006

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: AstraZeneca PLC

Deal Size: $377.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement August 04, 2020

Details:

Under the terms of the exclusive global agreement, AstraZeneca will take RXC006 forward into clinical development, targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF).

Orion Biotechnology

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Orion Biotechnology Receives Funding to Test OB-002 for Treatment of COVID-19

Lead Product(s): OB-002

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: OB-002

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: National Research Council Industrial Research Assistance Program

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Funding July 30, 2020

Details:

Funding from the National Research Council Industrial Research Assistance Program will support the development of Orion’s lead compound, OB-002, a promising treatment for SARS-CoV-2 infection associated acute respiratory distress syndrome (ARDS).

9 Meters Biopharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

9 Meters Biopharma Announces Issuance of Patent for Use of Larazotide in Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome

Lead Product(s): Larazotide Acetate

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: INN-202

Highest Development Status: Preclinical Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 28, 2020

Details:

U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent for Use of Tight Junction Antagonists in the Treatment of Acute Lung Injury and Acute Respiratory Distress, relating to its proprietary investigational agent, larazotide.

Fairhaven Pharmaceuticals

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Liminal BioSciences Broadens R&D Pipeline With Novel Preclinical Program for Eosinophilic-Driven Diseases

Lead Product(s): Undisclosed

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Liminal BioSciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition July 17, 2020

Details:

With this acquisition, Liminal gains a preclinical research program of small molecule antagonists. Investigational therapies developed in this program target a key chemoattractant and activator of eosinophils, which play a key role in Type 2 inflammation-driven diseases.

Find

Find Drugs for Pulmonary/Respiratory Diseases in Preclinical Development

Preclinical

Product Type

Companies

Cynata Therapeutics

Cymerus MSCs Demonstrate Efficacy in Preclinical Lung Disease Study

BioAegis Therapeutics

BioAegis Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia

ContraFect Corporation

Contrafect Announces Funding Agreement with the Cystic Fibrosis Foundation

Morphic Therapeutic

Morphic Announces that Abbvie Exercises License Option to Αvβ6 Integrin Inhibitor Program, Including Morf-720, for Fibrotic Diseases

Asalyxa Bio

Asalyxa Bio Launches with Novel Neutrophil-Targeting Drug Delivery Platform Technology and Lead Candidate, ASX-100

Nuformix

Nuformix Reports Results from Pre-clinical Pilot Study in IPF for NXP004 Programme

Redx Pharma

Redx Signs Out Licensing Agreement With Astrazeneca

Orion Biotechnology

Orion Biotechnology Receives Funding to Test OB-002 for Treatment of COVID-19

9 Meters Biopharma

9 Meters Biopharma Announces Issuance of Patent for Use of Larazotide in Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome

Fairhaven Pharmaceuticals

Liminal BioSciences Broadens R&D Pipeline With Novel Preclinical Program for Eosinophilic-Driven Diseases